Patent intelligence · US
US 8614183
Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
Patent details — US 8614183
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 24, 2013
- Expiration
- Dec 19, 2033
- Applicant
- Five Prime Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K38/179, A61K38/1825, A61P
Quick answer
US 8614183 (Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2) is held by Five Prime Therapeutics, Inc.. Status: granted. Granted Dec 24, 2013. Expires Dec 19, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K38/179, A61K38/1825, A61P, A61P35/00
More from Five Prime Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404275
Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
granted -
US 12383582
Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
granted -
US 12377115
Combination immunotherapies for treatment of cancer
granted -
US 12365719
CD80 extracellular domain polypeptides and their use in cancer treatment
granted -
US 12319738
Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
granted -
US 12304898
Quinolyl-containing compound and pharmaceutical composition, and use thereof
granted -
US 12234302
Chitosan derivatives and methods for preparing the same
granted -
US 12233119
Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
granted
Frequently asked questions
What is US patent 8614183?
US 8614183 (Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2) is held by Five Prime Therapeutics, Inc.. Status: granted. Granted Dec 24, 2013. Expires Dec 19, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8614183?
Five Prime Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 127 pharmaceutical patents for this assignee.
When does US 8614183 expire?
Our index shows an expiration date of Dec 19, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.